{"filing":{"accession_number":"0000950103-26-011876","cik":"0001356090","ticker":"PGEN","company_name":"PRECIGEN, INC.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"dp251262_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1356090/000095010326011876/dp251262_8k.htm"},"events":[{"id":23800,"run_id":21526,"accession_number":"0000950103-26-011876","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Precigen's second quarter 2026 financial results. The filing explicitly states that \"Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated August 4, 2026, reporting its financial results for the quarter ended June 30, 2026.\" The press release reports Q2 2026 revenues of $55.0 million (driven by PAPZIMEOS commercial sales of $53.1 million), net income of $20.1 million, and detailed financial comparisons to the prior year period. This is material as it demonstrates the company's transition to profitability and strong commercial momentum for its lead product.","company_name":"PRECIGEN, INC.","ticker":"PGEN","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24136,"accession_number":"0000950103-26-011876","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Precigen's second quarter 2026 financial results. The filing explicitly states that \"Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated August 4, 2026, reporting its financial results for the quarter ended June 30, 2026.\" The press release reports Q2 2026 revenues of $55.0 million (driven by PAPZIMEOS commercial sales of $53.1 million), net income of $20.1 million, and detailed financial comparisons to the prior year period. This is material as it demonstrates the company's transition to profitability and strong commercial momentum for its lead product.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:18:22.771767+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24136,"accession_number":"0000950103-26-011876","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Precigen's second quarter 2026 financial results. The filing explicitly states that \"Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated August 4, 2026, reporting its financial results for the quarter ended June 30, 2026.\" The press release reports Q2 2026 revenues of $55.0 million (driven by PAPZIMEOS commercial sales of $53.1 million), net income of $20.1 million, and detailed financial comparisons to the prior year period. This is material as it demonstrates the company's transition to profitability and strong commercial momentum for its lead product.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:18:22.771767+00:00","company_name":"PRECIGEN, INC.","ticker":"PGEN","filing_date":"2026-08-04"}]}